#1 Clinical Trials Search in Europe

Sodium O-Acetyl-(R)-Isoxazol-3-Yl((2-Oxo-3-(2,3,5-Trifluoro-4-(4-Oxo-3,4-Dihydropyridin-1(2H)-Yl)Phenyl)Oxazolidin-5-Yl)Methyl)Phosphoramidate

This article discusses the ongoing clinical trials of Contezolid Acefosamil, a new drug being tested for the treatment of moderate to severe diabetic foot infections. The study aims to compare the safety and effectiveness of Contezolid Acefosamil and its related compound Contezolid to the established antibiotic Linezolid. This Phase 3 trial involves multiple centers and uses a randomized, double-blind approach to evaluate the drug’s performance in adult patients with diabetic foot infections.

Table of Contents

What is Contezolid Acefosamil?

Contezolid Acefosamil is a new medication being studied for the treatment of diabetic foot infections. Its scientific name is sodium o-acetyl-(r)-isoxazol-3-yl((2-oxo-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2h)-yl)phenyl)oxazolidin-5-yl)methyl)phosphoramidate. It’s also known by other names such as C14042855-E, MRX-1367, or MRX-4[1].

How Does It Work?

Contezolid Acefosamil belongs to a class of antibiotics called oxazolidinones. These antibiotics work by stopping the growth of bacteria. It’s being developed as an alternative to an existing antibiotic called linezolid, which is also an oxazolidinone[1].

What Conditions Does It Treat?

The primary condition that Contezolid Acefosamil is being studied for is diabetic foot infections. These are infections that occur in the feet of people with diabetes. They can be serious and may lead to complications if not treated properly[1].

Clinical Trial Information

Contezolid Acefosamil is currently being studied in a Phase 3 clinical trial. This is an advanced stage of research where the drug is tested on a large group of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow it to be used safely[1].

The main goals of this study are:

  1. To evaluate how well Contezolid Acefosamil works compared to linezolid in treating diabetic foot infections[1].
  2. To assess the safety and tolerability of Contezolid Acefosamil compared to linezolid[1].

The researchers will look at several factors, including:

  • How well the infection responds to treatment after 35 days[1].
  • How quickly the signs of infection (like redness, swelling, and warmth) improve[1].
  • Whether there are any serious complications, such as death or need for amputation[1].

Who Can Receive This Medication?

The clinical trial has specific criteria for who can participate. Generally, participants must:

  • Be 18 years or older[1].
  • Have diabetes (type 1 or 2)[1].
  • Have a moderate to severe foot infection that started recently (within the past 14 days)[1].

However, there are many factors that might prevent someone from participating in the trial. For example, people with certain medical conditions, those who are pregnant or breastfeeding, or those who have recently taken certain medications may not be eligible[1].

Potential Side Effects and Precautions

As Contezolid Acefosamil is still being studied, not all potential side effects are known. However, based on its similarity to other oxazolidinone antibiotics, there are some precautions:

  • It may interact with certain medications, particularly those that affect serotonin levels in the brain[1].
  • People with a history of seizures or conditions that increase seizure risk may need to be monitored closely[1].
  • It may not be suitable for people with certain liver, kidney, or blood disorders[1].

It’s important to note that these are potential risks based on similar medications. The ongoing clinical trial will provide more information about the specific side effects and safety profile of Contezolid Acefosamil.

Aspect Details
Drug Name Contezolid Acefosamil (also known as MRX-4)
Trial Phase Phase 3
Condition Studied Moderate to Severe Diabetic Foot Infections
Comparison Drug Linezolid
Administration Routes Intravenous (IV) and Oral (PO)
Primary Objectives Evaluate clinical response at Day 35 and assess safety and tolerability
Key Secondary Objectives Evaluate clinical and microbiological responses at various timepoints
Treatment Duration Up to 28 days
Follow-up Period Up to 35 days from start of treatment

FAQ

  • What is Contezolid Acefosamil? Contezolid Acefosamil is a new antibiotic drug being tested for the treatment of moderate to severe diabetic foot infections. It belongs to the oxazolidinone class of antibiotics and is being compared to Linezolid in clinical trials.
  • What is the main goal of this clinical trial? The main goal is to evaluate the safety and effectiveness of Contezolid Acefosamil and Contezolid compared to Linezolid in treating adults with moderate or severe diabetic foot infections.
  • Who can participate in this clinical trial? Adults (18 years or older) with diabetes mellitus who have a moderate or severe foot infection that started within the past 14 days may be eligible. There are specific inclusion and exclusion criteria that determine eligibility.
  • How long does the treatment last in this trial? The treatment period can last up to 28 days, with follow-up assessments conducted up to 35 days after starting treatment.
  • What are some of the key outcomes being measured? The trial is measuring clinical response to treatment, microbiological response, safety and tolerability of the drugs, and a composite endpoint including death, unplanned amputation, and infectious complications.

Ongoing Clinical Trials on Sodium O-Acetyl-(R)-Isoxazol-3-Yl((2-Oxo-3-(2,3,5-Trifluoro-4-(4-Oxo-3,4-Dihydropyridin-1(2H)-Yl)Phenyl)Oxazolidin-5-Yl)Methyl)Phosphoramidate

  • Study on the Safety and Effectiveness of Contezolid Acefosamil, Contezolid, and Linezolid for Adults with Moderate or Severe Diabetic Foot Infections

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia Czechia Estonia France Greece +9

Glossary

  • Diabetic Foot Infection: An infection that occurs in the foot of a person with diabetes, often due to poor circulation and nerve damage. It can be serious and may lead to amputation if not treated properly.
  • Phase 3 Clinical Trial: A large-scale study to confirm the safety and efficacy of a new drug, typically involving hundreds to thousands of participants.
  • Randomized, Double-Blind Study: A type of clinical trial where participants are randomly assigned to different treatment groups, and neither the participants nor the researchers know who is receiving which treatment.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Oral (PO): A method of taking medication by mouth, such as pills or liquids.
  • Microbiological Response: The effect of treatment on the bacteria causing the infection, usually measured by laboratory tests.
  • Clinical Response: The visible or measurable improvement in a patient's condition following treatment.
  • Oxazolidinone: A class of antibiotics that includes drugs like Linezolid and the experimental drug Contezolid Acefosamil.
  • MITT Analysis Set: Modified Intent-to-Treat analysis, a method of analyzing clinical trial results that includes all participants who received at least one dose of the study drug.
  • End-of-Therapy (EOT): The point at which a patient completes their course of treatment in a clinical trial.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-contezolid-acefosamil-contezolid-and-linezolid-for-adults-with-moderate-or-severe-diabetic-foot-infections/